Dr Rachel Hoyles
Qualifications
MA, MB BChir (Cantab), PhD, FRCP
GMC number: 4368412
Practising since: 1996
Specialties
Respiratory Medicine, General (internal) Medicine
Consultation times
- Thursday 9:30am - 5pm
About
Dr Rachel Hoyles is a consultant respiratory physician who is experienced in managing all respiratory conditions and has specialist expertise in interstitial lung disease. She provides comprehensive advice on the investigation and treatment of breathlessness, coughing, wheezing, abnormal Xrays and scans, lung scarring and inflammation (interstitial lung disease), asthma, smoking-related lung diseases including COPD, lung infection, and a broad range of general respiratory conditions. Dr Hoyles spends time to listen and get to the bottom of a problem if at all possible.
v Alongside her private practice, Dr Rachel Hoyles works in the NHS at Oxford University Hospitals NHS Foundation Trust and is the lead clinician for the Oxford Interstitial Lung Disease Service; her unit is one of few NHS England recognised specialist centres for interstitial lung disease (ILD) and an anti-fibrotic prescribing centre.
Dr Rachel Hoyles qualified in Cambridge and trained in London centred around the Royal Brompton Hospital before taking up her current consultant role in the Oxford Centre for Respiratory Medicine in 2009. She completed a successful clinical and translational PhD project at the Royal Brompton and Royal Free Hospitals investigating the role of lung injury in scleroderma-associated lung fibrosis. The PhD research culminated in winning the prestigious BTS/BLF Early Career Investigator of the Year Prize in 2008 and selection of her work to be presented at the American Thoracic Society ‘Outstanding Science Symposium: Scientific Breakthroughs of the Year’ in 2008.
Rachel has a national profile in ILD and is a regular speaker at national conferences. She was a previous member of the ILD Specialist Advisory Group for the British Thoracic Society and has held an advisory role with the British Lung Foundation.
Please note
Dr Hoyles is only accepting patients via referrals.
When booking online, please email referral oxford.respiratory@nuffieldhealth.com
Contact
PA email: oxford.respiratory@nuffieldhealth.com
or raluca.guta@nuffieldhealth.com
Special interests
- General Respiratory Medicine
- Investigation of breathlessness, cough and abnormal radiology
- Interstitial lung disease
Other interests
- Connective tissue diseases and the lung
Personal interests
Family, travel, garden design, and singing (badly).
Treatments and tests offered by Dr Rachel Hoyles at Nuffield Health
- Spirometry and FeNO Assessments
Locations Dr Rachel Hoyles works with
Related experience
Research
Dr Hoyles is principle investigator for a number of multi-national and national clinical trials in idiopathic pulmonary fibrosis, connective-tissue-ILD, and progressive pulmonary fibrosis, in Oxford. She has ongoing research interests in lung diseases associated with rheumatic disorders, blood biomarkers of lung disease. She has published one of few multi-centre randomised controlled trials in connective tissue disease-associated pulmonary fibrosis.
Publications:
Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-centre cohort study. BMJ Open Respir Res. 2023.
Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Res. 2023.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023.
RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023.
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. Respirology. 2021.
Therapeutic advances in Idiopathic Pulmonary Fibrosis. Fraser E, Hoyles RK. Clinical Medicine 2016.
Oxford Textbook of Rheumatology, The Respiratory System (book chapter) 2013.
An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor ß Receptor. Am J Respir Crit Care Med. 2011.
A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006.
Memberships
- British Thoracic Society (BTS)
- European Respiratory Society
- Royal College of Physicians
- British Medical Association
- General Medical Council
Other posts held
- Lead Clinician ILD Service, Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford
Insurers Dr Rachel Hoyles works with
Dr Rachel Hoyles works with the following private medical insurance providers:
- AIG Direct
- Allianz
- Aviva Health
- AXA Health
- AXA - Global Healthcare
- Benenden Health
- Bupa
- Bupa Global
- Bupa On Demand
- Cigna
- Cigna International
- CS Healthcare
- Exeter Family Friendly
- Healix
- Health-on-Line
- National Friendly Society
- PHC
- Police Mutual
- SAGA
- Simplyhealth
- Standard Life
- Vitality Health (Pru Health)
- WPA
Declaration
Dr Rachel Hoyles does not hold a share or financial interest in this hospital, another Nuffield Health hospital or the company.
Dr Rachel Hoyles does not have a share or financial interest in equipment used at this hospital or another Nuffield Health hospital.
Dr Rachel Hoyles does not hold any paid advisory role(s) at this hospital or on behalf of Nuffield Health.
Ask a question about this consultant
Fill in the form below and we'll get back to you within one working day. If it's urgent, you can call us on 01865 307728.
Thank you
A member of the team will respond to you soon.